《双磷酸盐和其他骨调节剂在乳腺癌辅助治疗中的应用：ASCO-OH(CCO)指南更新》解读

doi:10.16139/j.1007-9610.2024.05.07

外科理论与实践 ›› 2024, Vol. 29 ›› Issue (05): 405-408.doi: 10.16139/j.1007-9610.2024.05.07

《双磷酸盐和其他骨调节剂在乳腺癌辅助治疗中的应用：ASCO-OH(CCO)指南更新》解读

陆裕杰, 朱思吉()

上海交通大学医学院附属瑞金医院普外科乳腺疾病诊治中心，上海 200025

收稿日期:2024-08-12 出版日期:2024-09-25 发布日期:2025-01-23
通讯作者: 朱思吉，E-mail: zsj_mu@yeah.net
基金资助:
上海交通大学“交大之星”计划医工交叉研究基金(YG2024QNB05)

The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update

LU Yujie, ZHU Siji()

Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received:2024-08-12 Online:2024-09-25 Published:2025-01-23

摘要/Abstract

摘要：

骨调节剂(BMA)目前主要包括双膦酸盐(BP)和地舒单抗，可减少乳腺癌肿瘤骨转移引起的骨相关事件。Journal of Clinical Oncology于2022年1月在线刊发了2022版《双磷酸盐和其他骨调节剂在乳腺癌辅助治疗中的应用：ASCO-OH(CCO)指南更新》。新版指南提示应与所有有指征接受术后辅助治疗的绝经后早期乳腺癌病人，讨论BP辅助治疗。唑来膦酸、氯膦酸盐、伊班膦酸均为推荐药物，建议BP持续时长为2~3年。ABCSG-18与D-CARE研究的结果不一致，且缺乏直接比较地舒单抗与BP作为早期乳腺癌辅助治疗的研究数据，因此不建议使用地舒单抗用于辅助治疗。总之，BP在早期乳腺癌辅助治疗中的地位被进一步肯定，而地舒单抗的价值仍未明确。

关键词: 乳腺癌, 骨调节剂, 双膦酸盐, 辅助治疗

Abstract:

Bone-modifying agents (BMAs), including bisphosphonate (BP) and denosumab, can reduce bone-related events caused by breast cancer bone metastasis. “Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update” was published in Journal of Clinical Oncology in January 2022. The new “2022 version Guideline” suggested that the use of BP should be discussed for all postmenopausal patients with early breast cancer who are indicated for adjuvant therapy. Recommended drugs included zoledronate, clodronate, and ibandronate, and the recommended duration of BP was 2-3 years. Owing to the inconsistent results of the ABCSG-18 and D-CARE trials and the lack of data directly comparing denosumab with BP in early breast cancer, the use of denosumab in adjuvant therapy was not recommended. In conclusion, the role of BP in the adjuvant treatment of early breast cancer has been further affirmed, while the value of denosumab remains unclear.

Key words: Breast cancer, Bone-modifying agent(BMA), Bisphosphonates(BP), Adjuvant treatment

中图分类号:

R737.9

陆裕杰, 朱思吉. 《双磷酸盐和其他骨调节剂在乳腺癌辅助治疗中的应用：ASCO-OH(CCO)指南更新》解读[J]. 外科理论与实践, 2024, 29(05): 405-408.

LU Yujie, ZHU Siji. The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update[J]. Journal of Surgery Concepts & Practice, 2024, 29(05): 405-408.

参考文献 9

[1]	中国医师协会肿瘤医师分会乳腺癌学组, 中国抗癌协会国际医疗交流分会. 骨改良药物安全性管理专家共识[J]. 中华肿瘤杂志, 2021, 43(6):622-628.
	Breast Cancer Group, Chinese Medical Doctor Association, International Medical Society, Chinese Anti-Cancer Association. Expert consensus on safety management of bone-modifying agents[J]. Chin J Oncol, 2021, 43(6):622-628.
[2]	DHESY-THIND S, FLETCHER G G, BLANCHETTE P S, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer:a cancer care ontario and American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2017, 35(18):2062-2081.
[3]	GNANT M, PFEILER G, STEGER G G, et al. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18):disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(3):339-351.
[4]	COLEMAN R, FINKELSTEIN D M, BARRIOS C, et al. Adjuvant denosumab in early breast cancer (D-CARE):an international, multicentre, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21(1):60-72.
[5]	GRALOW J R, BARLOW W E, PATERSON A H G, et al. Phase Ⅲ randomized trial of bisphosphonates as adjuvant therapy in breast cancer:S0307[J]. J Natl Cancer Inst, 2020, 112(7):698-707.
[6]	FRIEDL T W P, FEHM T, MÜLLER V, et al. Prognosis of patients with early breast cancer receiving 5 years vs 2 years of adjuvant bisphosphonate treatment:a phase 3 randomized clinical trial[J]. JAMA Oncol, 2021, 7(8):1149-1157.
[7]	EISEN A, SOMERFIELD M R, ACCORDINO M K, et al. Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer:ASCO-OH (CCO) guideline update[J]. J Clin Oncol, 2022, 40(7):787-800.
[8]	Predict Breast:NHS PREDICT Tool[EB/OL]. [2024-08-12]. https://breast.predict.nhs.uk/.
[9]	Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer:meta-analyses of individual patient data from randomised trials[J]. Lancet, 2015, 386(10001):1353-1361.

[1]	徐旺旺1,2，许良凤1,2，刘宁徽3，律娜3. 基于多注意力卷积神经网络的乳腺癌组织学图像诊断[J]. J Shanghai Jiaotong Univ Sci, 2025, 30(1): 91-106.
[2]	宋达疆, 张天怡, 王志远, 等. 分叶游离下腹部皮瓣移植乳房再造的血管吻合方式选择 [J]. 组织工程与重建外科杂志, 2024, 20(4): 428-.
[3]	郝昆, 孙宇光, 王仁贵, 等. 抽吸减容术治疗乳腺癌术后上肢淋巴水肿[J]. 组织工程与重建外科杂志, 2024, 20(1): 69-.
[4]	赵鑫, 高鹏, 陈洁. 机器人辅助手术系统在乳腺癌治疗中的应用及前景[J]. 外科理论与实践, 2024, 29(05): 376-381.
[5]	曹希, 骆勇超, 沈松杰. 适合中国女性的乳腺癌筛查策略[J]. 外科理论与实践, 2024, 29(05): 382-388.
[6]	笪倩, 阮淼, 费晓春, 王朝夫. 人工智能在乳腺癌病理诊断中的应用及研究展望[J]. 外科理论与实践, 2024, 29(05): 389-395.
[7]	周驿航, 曾子威, 康亮. 直肠癌治疗器官保留策略：馅饼还是陷阱?[J]. 外科理论与实践, 2024, 29(05): 396-400.
[8]	韩梦圆, 陈小松. 遗传性乳腺癌风险基因检测与咨询：NCCN指南解读与瑞金医院临床实践[J]. 外科理论与实践, 2024, 29(05): 401-404.
[9]	张丰哲, 童一苇, 陈小松, 沈坤炜. 前哨淋巴结阴性乳腺癌病人非前哨淋巴结转移相关危险因素分析[J]. 外科理论与实践, 2024, 29(05): 409-413.
[10]	唐筱璐, 华鑫, 曹璐, 陈佳艺. 21基因检测在早期乳腺癌辅助放疗中的应用[J]. 外科理论与实践, 2024, 29(03): 270-276.
[11]	宋子甲, 赵任. 早期直肠癌器官保留的研究进展[J]. 外科理论与实践, 2024, 29(03): 211-216.
[12]	邵卫清, 陆录, 钦伦秀. 系统疗法改变肝癌外科的格局：机遇与挑战[J]. 外科理论与实践, 2024, 29(02): 93-98.
[13]	朱正纲. 联合抗血管生成、免疫检查点抑制剂与化疗在局部进展期胃癌新辅助治疗中的临床意义[J]. 外科理论与实践, 2024, 29(02): 132-137.
[14]	欧丹, 蔡钢, 陈佳艺. RAD51AP1基因表达在三阴性乳腺癌脑转移中的生物信息分析[J]. 诊断学理论与实践, 2024, 23(02): 146-154.
[15]	刘娟, 殷丽娟, 范德生. AR、SKP2、SOX10、PD-L1及TIL表达在三阴性乳腺癌中的意义[J]. 诊断学理论与实践, 2024, 23(02): 162-172.

《双磷酸盐和其他骨调节剂在乳腺癌辅助治疗中的应用：ASCO-OH(CCO)指南更新》解读

The interpretation of Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 9

相关文章 15

编辑推荐

Metrics

本文评价